Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas

Abstract

Functional inactivation of tumor susceptibility gene tsg101 leads to cellular transformation and tumorigenesis in mice. While human TSG101 is located in a region where frequent loss of heterozygosity can be detected in a variety of cancers, no genomic deletion in TSG101 gene has been reported, casting a doubt on the role of TSG101 as a classical tumor suppressor. Some studies have revealed that TSG101 is a frequent target of splicing defects, which correlate with cellular stress and p53 status. Furthermore, recent reports have identified TSG101 as a part of the MDM2/p53 regulatory circuitry, a well-recognized circuitry that upon deregulation results in tumorigenesis. Interestingly, overexpression of tsg101 from an adventitious promoter also leads to neoplastic transformation. On the basis of this information, we have analysed TSG101 gene expression in 20 human papillary thyroid carcinomas (PTCs) by immunohistochemistry and demonstrated that the overexpression of TSG101 protein is closely associated with human PTCs. Further sequence analysis reveals no mutation in cDNA region encoding steadiness box in these PTC specimens, indicating that the upregulation of TSG101 protein is not caused by the alteration of this region. In situ hybridization analysis confirms that overexpression of TSG101 also occurs at the transcriptional level. In addition, semi-quantitative RT–PCR and subsequent Southern hybridization verify that the amounts of TSG101 transcripts are indeed lower in three normal thyroid tissues than in PTC specimens. Here we report the upregulation of TSG101 expression in PTC cells, providing the first evidence of the association of TSG101 overexpression with human tumors and suggesting that upregulation of TSG101 steady-state level might play a role in mediating tumorigenesis of human PTC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

Abbreviations

TSG101:

tumor susceptibility gene 101

PTC:

papillary thyroid carcinoma

IHC:

immunohistochemistry

ISH:

in situ hybridization

GST:

glutathione S-transferase

References

  • Ali IU, Lidereau R, Theillet C, Callahan R . 1987 Science 238: 185–188

  • Babst M, Odorizzi G, Estepa EJ, Emr SD . 2000 Traffic 1: 248–258

  • Baffa R, Negrini M, Mandes B, Rugge M, Ranzani GN, Hirohashi S, Croce CM . 1996 Cancer Res. 56: 268–272

  • Bishop N, Woodman P . 2000 J. Biol. Chem. 276: 11735–11742

  • Byrne JA, Simms LA, Little MH, Algar EM, Smith PJ . 1993 Genes Chrom. Cancer 8: 104–111

  • Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA . 1998 J. Soc. Gynecol. Investig. 5: 281–285

  • Chang JG, Su TH, Wei HJ, Wang JC, Chen YJ, Chang CP, Jeng CJ . 1999 Br. J. Cancer 79: 445–450

  • Feng GH, Lih CJ, Cohen SN . 2000 Cancer Res. 60: 1736–1741

  • Hittelman AB, Burakov D, Iñiguez-Lluhí JA, Freedman LP, Garabedian MJ . 1999 EMBO J. 18: 5380–5388

  • Hsu SF, Chang AC, Wang JK, Cheng JT . 1998 Hybridoma 17: 251–255

  • Jennings T, Bratslavsky G, Gerasimov G, Troshina K, Bronstein M, Dedov I, Alexandrova G, Figge J . 1995 Exp. Mol. Pathol. 62: 199–206

  • Koonin EV, Abagyan RA . 1997 Nat. Genet. 16: 330–331

  • Lee MP, Feinberg AP . 1997 Cancer Res. 57: 3131–3134

  • Li L, Cohen SN . 1996 Cell 85: 319–329

  • Li L, Li X, Francke U, Cohen SN . 1997 Cell 88: 143–154

  • Li L, Liao J, Ruland J, Mak TW, Cohen SN . 2001 Proc. Natl. Acad. Sci. USA 98: 1619–1624

  • Lin PM, Liu TC, Chang JG, Chen TP, Lin SF . 1998a Br. J. Haematol. 102: 753–758

  • Lin SY, Chen YJ, Chang JG . 1998b J. Gastroenterol. Hepatol. 13: 1111–1114

  • Lothe RA, Hastie N, Heimdal K, Fossa SD, Stenwig AE, Borresen AL . 1993 Genes Chrom. Cancer 7: 96–101

  • Ludwig CU, Raefle G, Dalquen P, Stulz P, Stahel R, Obrecht JP . 1991 Int. J. Cancer 49: 661–665

  • Maucuer A, Camonis JH, Sobel A . 1995 Proc. Natl. Acad. Sci. USA 92: 3100–3104

  • McIver B, Grebe SK, Wang L, Hay ID, Yokomizo A, Liu W, Goellner JR, Grant CS, Smith DI, Eberhardt NL . 2000 Clin. Endocrinol. (Oxf) 52: 749–757

  • Moyret-Lalle C, Duriez C, Van Kerckhove J, Gilbert C, Wang Q, Puisieux A . 2001 Cancer Res. 61: 486–488

  • Ponting CP, Cai YD, Bork P . 1997 J. Mol. Med. 75: 467–489

  • Reeve AE, Sih SA, Raizis AM, Feinberg AP . 1989 Mol. Cell. Biol. 9: 1799–1803

  • Rountree MR, Bachman KE, Baylin SB . 2000 Nat. Genet. 3: 269–277

  • Ruland J, Sirard C, Elia A, MacPherson D, Wakeham A, Li L, de la Pompa JL, Cohen SN, Mak TW . 2001 Proc. Natl. Acad. Sci. USA 98: 1859–1864

  • Shaw ME, Knowles MA . 1995 Genes Chrom. Cancer 13: 1–8

  • Sun Z, Pan J, Hope WX, Cohen SN, Balk SP . 1999 Cancer 86: 689–696

  • Turpin E, Dalle B, de Roquancourt A, Plassa LF, Marty M, Janin A, Beuzard Y, de The H . 1999 Oncogene 18: 7834–7837

  • Wang NM, Chang JG, Liu TC, Lin SF, Peng CT, Tsai FJ, Tsai CH . 2000 Int. J. Oncol. 16: 75–80

  • Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J, Kato S . 1998 Biochem. Biophys. Res. Commun. 245: 900–905

  • Weitzel JN, Patel J, Smith DM, Goodman A, Safaii H, Ball HG . 1994 Gynecol. Oncol. 55: 245–252

  • Willeke F, Ridder R, Bork P, Klaes R, Mechtersheimer G, Schwarzbach M, Zimmer D, Kloor M, Lehnert T, Herfarth C, von Knebel Doeberitz M . 1998 Mol. Carcinog. 23: 195–200

  • Xie W, Li L, Cohen SN . 1998 Proc. Natl. Acad. Sci. USA 95: 1595–1600

  • Zhong Q, Chen Y, Jones D, Lee WH . 1998 Cancer Res. 58: 2699–2702

Download references

Acknowledgements

We thank Ms Shang-Yun Liu for the assistance in immunohistochemical analysis. This work is supported in part by National Science Council grants NSC 88-2314-B-182A-046 (to R-T Liu), NSC 88-2314-B-110-007 and VGHNSU88-07 (to J-T Cheng).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiin-Tsuey Cheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, RT., Huang, CC., You, HL. et al. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21, 4830–4837 (2002). https://doi.org/10.1038/sj.onc.1205612

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205612

Keywords

This article is cited by

Search

Quick links